GoodRx Holdings (GDRX) Long-Term Deferred Tax (2019 - 2026)

GoodRx Holdings has disclosed Long-Term Deferred Tax across 7 years of filings, most recently posting $53.0 million for Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $53.0 million, down 31.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $53.0 million (down 31.28% YoY), and the FY2025 annual result was $57.1 million, down 26.0% from the prior year.
• Long-Term Deferred Tax came in at $53.0 million for Q1 2026 at GoodRx Holdings, down from $57.1 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $77.2 million in Q4 2024 to a low of $53.0 million in Q1 2026.
• The 4-year median for Long-Term Deferred Tax is $65.3 million (2023), against an average of $66.1 million.
• Across the five-year window, Long-Term Deferred Tax gained 18.25% in 2024 and slumped 31.28% in 2026, its largest moves.
• GoodRx Holdings' Long-Term Deferred Tax stood at $65.3 million in 2023, then increased by 18.25% to $77.2 million in 2024, then fell by 26.0% to $57.1 million in 2025, then declined by 7.12% to $53.0 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $53.0 million (Q1 2026), $57.1 million (Q4 2025), and $69.1 million (Q3 2025), per Business Quant data.